Acceptability and Cost Effectiveness of Home Based Management of Fever: Different Strategies
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Malaria remains a major cause of morbidity and mortality particularly among children < 5 years in Uganda. Due to inaccessibility many children die before they reach the health facility. The Home Based Management of Fever (HBMF) strategy was adopted in Uganda as a mean to improve access to early and appropriate treatment of fever at community level. Pre-packed chloroquine with sulphadoxine-pyrimethamine (HOMAPAK) is provided through Community Drug Distributors(CDDs). Initial evaluation showed underutilization of the CDDs (15%). This cast doubt on community acceptability, accessibility as well as its feasibility and cost effectiveness. This 3-year project intends to compare community acceptability and cost effectiveness of two HOMAPAK distribution methods. The current CDD-based HOMAPAK distribution versus home-based HOMAPAK distribution. The study hypothesis is that "home-based HOMAPAK distribution is more acceptable to the community and more cost effective than the CDD based HOMAPAK A non randomised community study will be conducted in two sub-counties of Mukono district. In the control arm, HOMAPAKs will be distributed through the CDDs while in the intervention arm, HOMAPAKs will be directly distributed to the caretakers in the homes. The study population are caretakers and their children < 5 years. At baseline a survey (Phase 1) with a sample size 657 in each study area will assess the common drugs stocked at home to treat malaria and the health seeking behaviour for malaria for children < 5 years and to determine the prevalence of malaria parasitaemia and anaemia among children < 5 years. Phase 2 includes the intervention. The villages will be assigned to either the control or intervention arm. Anaemia and malaria parasitaemia among children with fever will be assessed through active case finding. The impact of either distribution system on accessibility, acceptability, sustainability, compliance, cost effectiveness and malaria morbidity will be assessed during the evaluation phase. Health education messages on malaria prevention and treatment will be given to both communities. Drug misuse will be limited by distributing HOMAPAKs according to the number of children <5years in each household. HOMAPAK will only be replenished after the caretaker returns a used packet to the CDD.
| Condition | Intervention |
|---|---|
|
Fever Anaemia Malaria |
Drug: Chloroquine, sulphadoxine-pyrimethamine |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Community Acceptability and Cost-effectiveness of Two Drug Distribution Methods for Home Based Management of Fevr in Kayunga District, Uganda |
- See detailed description
- See detailed description
| Estimated Enrollment: | 1314 |
| Study Start Date: | November 2005 |
| Estimated Study Completion Date: | November 2008 |
| Estimated Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
Show Detailed Description
Eligibility| Ages Eligible for Study: | up to 59 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- children 0-59 months with fever
Contacts and Locations| Uganda | |
| Kayunga District | |
| Kayunga, Uganda | |
| Principal Investigator: | Robinah Najjembe, MD, MPH | Makerere University Institute of Public Health |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00259142 History of Changes |
| Other Study ID Numbers: | UGA.5.2RNA2005 |
| Study First Received: | November 25, 2005 |
| Last Updated: | January 11, 2010 |
| Health Authority: | Uganda: Research Ethics Committee |
Keywords provided by DBL -Institute for Health Research and Development:
|
home management of fever, malaria, Uganda |
Additional relevant MeSH terms:
|
Anemia Fever Malaria Hematologic Diseases Body Temperature Changes Signs and Symptoms Protozoan Infections Parasitic Diseases Chloroquine Chloroquine diphosphate Pyrimethamine Sulfadoxine Sulfadoxine-pyrimethamine Amebicides Antiprotozoal Agents |
Antiparasitic Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Antimalarials Antirheumatic Agents Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Filaricides Antinematodal Agents |
ClinicalTrials.gov processed this record on May 16, 2013